A Phase 3 interventional study of Somatropin and Somatropin in Growth Hormone Deficiency, sponsored by Eli Lilly and Company. Completed at 10 sites in Italy. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2009-06-10.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 42nd largest by enrollment, is one of 5 that started in 2004, is one of 23 in phase 3, and was the 9th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: Up to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 4 studies filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early pubertal children with growth hormone deficiency (GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled dosage group (group B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Doubled dosage
Drug: Somatropin
In-label dosage
Drug: Somatropin
Doubled dosage with respect to the pre-enrollment (in-label) dosage
Also known as: LY137998, Humatrope
In-label dosage
Also known as: LY137998, Humatrope
Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint
Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.
Time frame: 12-Months
Change From Baseline to 12-Month and 24-Month Endpoints in Height Standard Deviation Score (SDS)
This was derived by subtracting the age-and-gender-matched population 50th percentile height from the patient's height and then dividing this value by the age-and-gender-matched population height SD.
Time frame: Baseline, 12-Months, 24-Months
Height Velocity Standard Deviation Score (SDS) at 24 Month Endpoint
Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.
Time frame: 24 Months
| Milestone | High Dose Somatropin | Label Dose Somatropin |
|---|---|---|
| Started | 14 | 13 |
| Completed | 12 | 11 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Participant moved away | 0 | 1 |
Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.
| standard deviation score | High Dose Somatropin | Label Dose Somatropin |
|---|---|---|
| Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint | 1.83 ± 0.91 | 1.38 ± 1.41 |
This was derived by subtracting the age-and-gender-matched population 50th percentile height from the patient's height and then dividing this value by the age-and-gender-matched population height SD.
| standard deviation score | High Dose Somatropin | Label Dose Somatropin |
|---|---|---|
| 12-Month Height SDS Change (N=14, N=12) | 0.49 ± 0.12 | 0.34 ± 0.13 |
| 24-Month Height SDS Change (N=13, N=11) | 0.88 ± 0.17 | 0.40 ± 0.18 |
Height velocity (difference between 2 height measurements, divided by years elapsed between measurements) SDS was derived by subtracting age and gender-matched population mean height velocity from patient's height velocity (based on measurements 12 months apart) then dividing this value by age and gender-matched population height velocity SD.
| standard deviation score | High Dose Somatropin | Label Dose Somatropin |
|---|---|---|
| Height Velocity Standard Deviation Score (SDS) at 24 Month Endpoint | 2.58 ± 1.86 | 1.45 ± 1.06 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose Somatropin | — | — | — |
| Label Dose Somatropin | — | — | — |
| Event | High Dose Somatropin | Label Dose Somatropin |
|---|---|---|
| Vertebral injuryInjury, poisoning and procedural complications | 1/14 | 0/13 |
| Event | High Dose Somatropin | Label Dose Somatropin |
|---|---|---|
| HeadacheNervous system disorders | 3/14 | 0/13 |
| GynaecomastiaReproductive system and breast disorders | 3/14 | 1/13 |
| PyrexiaGeneral disorders | 2/14 | 2/13 |
| InfluenzaInfections and infestations | 2/14 | 0/13 |
| Insulin resistanceMetabolism and nutrition disorders | 2/14 | 0/13 |
| ScoliosisMusculoskeletal and connective tissue disorders | 2/14 | 0/13 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/14 | 1/13 |
| RetinoschisisEye disorders | 0/14 | 1/13 |
| Genital infectionInfections and infestations | 0/14 | 1/13 |
| PharyngitisInfections and infestations | 1/14 | 1/13 |
| Age Continuous(years) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Mean | 13.5 ± 1.2 | 13.0 ± 1.5 | 13.3 ± 1.3 |
| Sex: Female, Male(Participants) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Female | 1 | 3 | 4.0 |
| Male | 13 | 10 | 23.0 |
| Region of Enrollment(participants) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Italy | 14 | 13 | 27.0 |
| Race/Ethnicity(participants) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Caucasian | 14 | 12 | 26.0 |
| Other | 0 | 1 | 1.0 |
| Baseline Predicted Height(centimeters) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Mean | 168 ± 6.8 | 169 ± 10.7 | 168 ± 8.7 |
| Baseline Predicted Height Standard Deviation Score (SDS)(standard deviation score) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Mean | -0.9 ± 0.8 | -0.5 ± 1.0 | -0.7 ± 0.9 |
| Body Mass Index(kilograms per square meter (kg/m2)) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Mean | 18.9 ± 3.2 | 19.4 ± 3.7 | 19.2 ± 3.4 |
| Bone Age(years) | High Dose Somatropin | Label Dose Somatropin | Total |
|---|---|---|---|
| Mean | 12.4 ± 0.7 | 12.1 ± 1.0 | 12.2 ± 0.8 |
4 further baseline measures are reported on the registry.
The record gives a start of Mar 2004, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone